天津医药

天津医药 ›› 2026, Vol. 54 ›› Issue (1): 92-96.doi: 10.11958/20252619

• 药物临床观察 • 上一篇    下一篇

火把花根片对中度特应性皮炎患者的临床疗效研究

王文文(), 董垚, 赵璐, 任鲁宁, 杜红阳△()   

  1. 锦州医科大学附属第一医院皮肤科（邮编121000）
  • 收稿日期:2025-07-31 修回日期:2025-10-05 出版日期:2026-01-15 发布日期:2026-01-19
  • 通讯作者: △ E-mail：4197123@163.com
  • 作者简介:王文文（2000），女，硕士在读，主要从事特应性皮炎方面研究。E-mail：18753707976@163.com
  • 基金资助:
    辽宁省科技计划联合计划项目(2024JH2/102600117);辽宁省研究生教育教学改革研究项目(LNYJG2024216);陈孝平科技发展基金会“2022年度免疫性疾病研究槐杞黄专项基金”项目(CXPJJH12203-16);辽宁省教育科学“十四五”规划课题(JG25DB171);辽宁省教育科学“十四五”规划课题(JG24DB135)

Clinical efficacy of colquhounia root tablets in patients with moderate atopic dermatitis

WANG Wenwen(), DONG Yao, ZHAO Lu, REN Luning, DU Hongyang△()   

  1. Department of Dermatology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China
  • Received:2025-07-31 Revised:2025-10-05 Published:2026-01-15 Online:2026-01-19
  • Contact: △ E-mail：4197123@163.com

RichHTML

0

PDF (PC)

8

摘要：

目的 探讨火把花根片对中度特应性皮炎（AD）患者临床疗效及炎症指标的影响。方法 前瞻性纳入80例中度AD患者，随机分为对照组和试验组，每组40例，最终对照组完成33例，试验组完成32例。对照组口服盐酸氮卓斯汀片与枸地氯雷他定胶囊，外部涂抹糠酸莫米松乳膏与复方多黏菌素B软膏。试验组在上述治疗基础上口服火把花根片（4片/次，3次/日），所有患者均接受8周的治疗。评估2组患者的临床应答率。于治疗前后检测并计算外周血中性粒细胞计数/淋巴细胞计数比值（NLR）、嗜酸性粒细胞计数/淋巴细胞计数比值（ELR）、单核细胞计数/淋巴细胞计数比值（MLR）、血小板计数/淋巴细胞计数比值（PLR）及血清总免疫球蛋白（IgE）。并记录湿疹面积和严重程度指数（EASI）、瘙痒数字评价量表（PP-NRS）、研究者整体评分法（IGA）和特应性皮炎（SCORAD）评分。结果 试验组临床应答率显著高于对照组（68.8% vs. 39.4%，P=0.033），且治疗后NLR和IgE水平较对照组下降（P<0.05），临床EASI、IGA和SCORAD评分降低幅度大于对照组（P<0.05）。治疗期间2组患者不良反应事件发生率无明显差异（6.06% vs. 9.38%，χ2=0.251，P=0.672）。结论 火把花根片可改善中度AD患者临床症状，降低炎症指标水平，且整体安全性较高。

关键词: 皮炎, 特应性, 火把花根片, 炎症指标, 临床疗效

Abstract:

Objective To explore the influence of colquhounia root tablets on the clinical efficacy and inflammatory indicators in patients with moderate atopic dermatitis (AD). Methods A total of 80 patients with moderate AD were prospectively included in this study. Patients were randomly divided into the control group and the test group, with 40 patients in each group. Ultimately, 33 patients in the control group and 32 in the test group were completed the study. The control group received oral hydroxyzine hydrochloride tablets and cetirizine hydrochloride capsules, and externally applied mometasone furoate cream and polymyxin B compound ointment. The test group received the same treatment along with oral Colquhounia root tablets (4 tablets per dose, 3 doses per day). All patients underwent 8 weeks of treatment. Clinical response rates were evaluated in both groups. Before and after treatment, peripheral blood samples were taken to measure and calculate the neutrophil/lymphocyte ratio (NLR), eosinophil/lymphocyte ratio (ELR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR) and serum total immunoglobulin E (IgE) levels. Additionally, eczema area and severity index (EASI), pruritus numeric rating scale (PP-NRS), investigator global assessment (IGA) and SCORAD scores were recorded. Results The clinical response rate was significantly higher in the test group than that of the control group (68.8% vs. 39.4%, P = 0.033). After treatment, the NLR and IgE levels were significantly lower in the test group than those of the control group (P < 0.05). Furthermore, the reduction in clinical scores (EASI, IGA, SCORAD) were more significant in the test group compared to those of the control group (P < 0.05). There was no significant difference in the incidence of adverse reaction events between the two groups during the treatment period (6.06% vs. 9.38%, χ2=0.251, P=0.672). Conclusion Colquhounia root tablets show significant efficacy in treating moderate atopic dermatitis by improving clinical symptoms and reducing inflammatory markers, and have a relatively high overall safety.

Key words: dermatitis, atopic, colquhounia root tablets, inflammatory markers, clinical efficacy

中图分类号: